Expanded Pre-Implantation Genomic Testing
EPⓖT allows the routine, inexpensive evaluation of hundreds of thousands of genetic variants, implementing a novel combination of embryo genotyping methods not previously combined into are productive genetics application. Among the genetic disorders whose phenotype risk can routinely be diagnosed by our genotyping methodology are:
Universal coverage of common single-gene disorders, such as Cystic Fibrosis, Thalassemia, BRCA, Sickle Cell Anemia, and Gaucher Disease Broad coverage of polygenic disorders, listed here.
As the first company to translate genomic predictors of polygenic disease risk into disease prevention through PGT, we set a world precedent for improved clinical care in IVF with our EPⓖT method.
Being able to detect chromosomal abnormalities, screen for single-gene disorders, and predict polygenic disease risks, EPⓖT is the most comprehensive genetic testing product ever created.
Traditional preimplantation genetic diagnosis (PGD) procedures only test for a small selection of specific single-gene disorders at a time. By simultaneously screening for hundreds of single-gene disorders, EPⓖT provides the most extensive analysis of single-gene disorder risks available, allowing couples to make the most informed decision possible.
EPⓖT is the first ever genetic test that allows for the risk evaluation of polygenic diseases — those genetic disorders which involve complex interactions of multiple genes, and which comprise the majority of known disorders with a genetic cause.